IN
INSM
INSMED Inc
$97.85
+1.17%
$21.2B
No data for this timeframe.
Vol
Market Cap$21.2B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (97%)
Inst. Holders50 funds
Inst. Value$20.1B
Inst. Activity34 buys / 16 sells
Insider Activity0B / 29S
Insider Net $-$17.2M
Reddit Sentiment80° Bullish
SEC Reports19
Recent Activity
Jun 8, 2026
Insider
Lewis William sold 6,515 shares
Chair and CEO @ $94.03 ($612.6K)
Jun 5, 2026
Insider
Flammer Martina M.D. sold 1,858 shares
Chief Medical Officer @ $103.78 ($192.8K)
Jun 3, 2026
Insider
Adsett Roger sold 2,370 shares
Chief Operating Officer @ $102.27 ($242.4K)
Jun 3, 2026
short_volume
Short Volume: INSM — 66.9% short (0.5M / 0.8M)
Short: 524,135 | Exempt: 105 | TRF Vol: 783,174 | Short Ratio: 66.9% | Off-exchange volume (dark poo
May 16, 2026
SEC
Morgan Stanley upgrades INSM to Overweight — PT $212 (+94%) as part of 7-firm cluster
ANALYST-UPGRADE — Impact 5/10
Apr 16, 2026
SEC
Truist Securities initiates coverage on INSM with a Buy rating and $48 price target, below the $214.79 mean target from
ANALYST-UPGRADE — Impact 5/10
Apr 16, 2026
SEC
Jefferies initiates INSM with a Buy rating and $105 price target, below the $160.18 current price and $214.79 mean conse
ANALYST-UPGRADE — Impact 5/10
Inst.
FMR LLC — ADD
13,160,167 shares ($2.2B)
Price Targets
$197.62
+102.0% upside
Strong Buy
Current $97.85
Low $140.00
Median $202.00
High $243.00
21 analysts
$140.00
$243.00
Analyst Ratings
9Strong Buy
19Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Jun 5, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 14, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| May 8, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 8, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.77 ▲ +1.2% | $-1.09 — $-0.58 | 55% YoY | 13 |
| Next Q | $-0.60 ▲ +0.6% | $-1.14 — $-0.35 | 66% YoY | 13 |
| Current FY | $-2.78 | $-4.29 — $-1.84 | 57% YoY | 14 |
| Next FY | $0.32 ▼ -2.7% | $-1.91 — $1.64 | 112% YoY | 15 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $2.7B | — |
| FMR LLC | $2.2B | ADD |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.7B | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.6B | — |
| BAKER BROS. ADVISORS LP | $1.2B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | Lewis William | SELL | $612.6K |
| Jun 5, 2026 | Flammer Martina | SELL | $192.8K |
| Jun 3, 2026 | Adsett Roger | SELL | $242.4K |
| Jun 3, 2026 | Smith Michael | SELL | $220.8K |
| Jun 3, 2026 | Bonstein Sara | SELL | $245.9K |
Reddit Sentiment
80°
Bullish
Bearish
Neutral
Bullish
50 institutional holders with $20.1B total value (122,824,361 shares) as of 2026-Q1. Top holders: BlackRock,, FMR, VANGUARD. Net buying activity: 34 institutions added/increased vs 16 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 16,678,146 | $2.7B | 13.6% | — |
| 2 | FMR LLC | 13,160,167 | $2.2B | 10.7% | ADD +32.6% |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 10,371,802 | $1.7B | 8.4% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 9,642,131 | $1.6B | 7.9% | — |
| 5 | BAKER BROS. ADVISORS LP | 7,421,111 | $1.2B | 6.0% | — |
| 6 | Artisan Partners Limited Partnership | 6,527,301 | $1.1B | 5.3% | ADD +34.8% |
| 7 | D. E. Shaw & Co., Inc. | 5,625,825 | $919.9M | 4.6% | — |
| 8 | Capital International Investors | 5,595,194 | $914.9M | 4.6% | — |
| 9 | STATE STREET CORP | 5,551,699 | $907.8M | 4.5% | — |
| 10 | RTW INVESTMENTS, LP | 4,842,880 | $791.9M | 3.9% | — |
| 11 | AMERIPRISE FINANCIAL INC | 3,057,718 | $500.0M | 2.5% | ADD +55.3% |
| 12 | FRANKLIN RESOURCES INC | 2,617,251 | $428.0M | 2.1% | — |
| 13 | CITADEL ADVISORS LLC | 2,182,571 | $356.9M | 1.8% | — |
| 14 | Invesco Ltd. | 1,988,968 | $325.2M | 1.6% | TRIM -27.1% |
| 15 | BANK OF AMERICA CORP /DE/ | 1,502,281 | $245.7M | 1.2% | — |
| 16 | SEI INVESTMENTS CO | 1,395,794 | $228.2M | 1.1% | ADD +56.8% |
| 17 | Capital World Investors | 1,362,291 | $222.7M | 1.1% | NEW |
| 18 | VANGUARD FIDUCIARY TRUST CO | 1,354,516 | $221.5M | 1.1% | — |
| 19 | MORGAN STANLEY | 1,331,542 | $217.7M | 1.1% | — |
| 20 | Castle Hook Partners LP | 1,269,754 | $207.6M | 1.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 9,927,936 | 13,160,167 | +32.6% | $2.2B | 2026-Q1 |
| Artisan Partners Limited Partnership | ADD | 4,843,749 | 6,527,301 | +34.8% | $1.1B | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 1,968,857 | 3,057,718 | +55.3% | $500.0M | 2026-Q1 |
| Invesco Ltd. | TRIM | 2,726,857 | 1,988,968 | -27.1% | $325.2M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 890,170 | 1,395,794 | +56.8% | $228.2M | 2026-Q1 |
| Capital World Investors | NEW | — | 1,362,291 | — | $222.7M | 2026-Q1 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | TRIM | 1,221,096 | 902,666 | -26.1% | $147.6M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 300,000 | 900,000 | +200.0% | $147.2M | 2026-Q1 |
| Legal & General Group Plc | ADD | 540,313 | 787,079 | +45.7% | $128.7M | 2026-Q1 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | ADD | 284,844 | 469,561 | +64.8% | $76.8M | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 328,328 | 467,753 | +42.5% | $76.5M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | TRIM | 800,555 | 419,304 | -47.6% | $68.6M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | TRIM | 646,714 | 396,245 | -38.7% | $64.8M | 2026-Q1 |
| Allspring Global Investments Holdings, LLC | ADD | 220,084 | 282,734 | +28.5% | $46.6M | 2026-Q1 |
| Neuberger Berman Group LLC | ADD | 207,869 | 270,700 | +30.2% | $44.3M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 380,561 | 221,707 | -41.7% | $36.3M | 2026-Q1 |
| TD ASSET MANAGEMENT INC | TRIM | 262,478 | 163,424 | -37.7% | $26.7M | 2026-Q1 |
| ExodusPoint Capital Management, LP | ADD | 80,087 | 148,133 | +85.0% | $24.2M | 2026-Q1 |
| FRED ALGER MANAGEMENT, LLC | ADD | 81,311 | 125,766 | +54.7% | $20.6M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | 67,389 | 119,958 | +78.0% | $19.6M | 2026-Q1 |
| PFA Pension, Forsikringsaktieselskab | DOUBLED | 48,330 | 114,788 | +137.5% | $18.8M | 2026-Q1 |
| NEOS Investment Management LLC | DOUBLED | 47,957 | 110,426 | +130.3% | $18.1M | 2026-Q1 |
| M&G Plc | NEW | — | 98,221 | — | $16.1M | 2026-Q1 |
| Swedbank AB | ADD | 59,552 | 82,865 | +39.1% | $13.6M | 2026-Q1 |
| Tredje AP-fonden | NEW | — | 76,604 | — | $12.5M | 2026-Q1 |
12 unique insiders with 50 transactions. Net insider value: -$17.2M ($0.00 bought, $17.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | Lewis William | Chair and CEO | SELL | 6,515 | $94.03 | $612.6K |
| Jun 5, 2026 | Flammer Martina M.D. | Chief Medical Officer | SELL | 1,858 | $103.78 | $192.8K |
| Jun 3, 2026 | Adsett Roger | Chief Operating Officer | SELL | 2,370 | $102.27 | $242.4K |
| Jun 3, 2026 | Smith Michael Alexander | Chief Legal Officer | SELL | 2,159 | $102.27 | $220.8K |
| Jun 3, 2026 | Bonstein Sara | Chief Financial Officer | SELL | 2,404 | $102.27 | $245.9K |
| Jun 3, 2026 | Lewis William | Chair and CEO | SELL | 7,605 | $102.27 | $777.8K |
| Jun 3, 2026 | Flammer Martina M.D. | Chief Medical Officer | SELL | 2,566 | $102.27 | $262.4K |
| May 22, 2026 | Smith Michael Alexander | Chief Legal Officer | SELL | 6,149 | $108.47 | $667.0K |
| May 18, 2026 | Lewis William | Chair and CEO | EXERCISE | 6,259 | $30.46 | $190.6K |
| May 18, 2026 | Lewis William | Chair and CEO | SELL | 5,753 | $105.32 | $605.9K |
| May 14, 2026 | Flammer Martina M.D. | Chief Medical Officer | SELL | 10,479 | $117.54 | $1.2M |
| May 13, 2026 | Flammer Martina M.D. | Chief Medical Officer | SELL | 4,470 | $112.76 | $504.0K |
| May 13, 2026 | Smith Michael Alexander | Chief Legal Officer | SELL | 4,109 | $116.18 | $477.4K |
| May 13, 2026 | SHAROKY MELVIN MD | Director | AWARD | 3,305 | — | — |
| May 13, 2026 | Adsett Roger | Chief Operating Officer | SELL | 5,837 | $116.18 | $678.1K |
| May 13, 2026 | Brennan David R | Director | AWARD | 3,305 | — | — |
| May 13, 2026 | Desjardins Clarissa | Director | AWARD | 3,305 | — | — |
| May 13, 2026 | LEE LEO | Director | AWARD | 3,305 | — | — |
| May 13, 2026 | Lewis William | Chair and CEO | SELL | 13,283 | $116.18 | $1.5M |
| May 13, 2026 | ANDERSON ELIZABETH M | Director | AWARD | 3,305 | — | — |
| May 13, 2026 | Bonstein Sara | Chief Financial Officer | SELL | 8,272 | $116.18 | $961.0K |
| May 13, 2026 | SCHAFER CAROL | Director | AWARD | 3,305 | — | — |
| May 11, 2026 | Flammer Martina M.D. | Chief Medical Officer | EXERCISE | 12,949 | $17.07 | $221.0K |
| May 11, 2026 | Flammer Martina M.D. | Chief Medical Officer | SELL | 12,119 | $100.35 | $1.2M |
| May 4, 2026 | Lewis William | Chair and CEO | SELL | 433 | $134.18 | $58.1K |
| May 4, 2026 | Lewis William | Chair and CEO | EXERCISE | 6,259 | $30.46 | $190.6K |
| Apr 16, 2026 | Lewis William | Chair and CEO | EXERCISE | 6,259 | $30.46 | $190.6K |
| Apr 16, 2026 | Lewis William | Chair and CEO | SELL | 2,246 | $142.99 | $321.2K |
| Apr 6, 2026 | Lewis William | Chair and CEO | EXERCISE | 6,259 | $30.46 | $190.6K |
| Apr 6, 2026 | Lewis William | Chair and CEO | SELL | 787 | $161.73 | $127.3K |
| Apr 1, 2026 | Adsett Roger | Chief Operating Officer | EXERCISE | 88,060 | $14.56 | $1.3M |
| Apr 1, 2026 | Adsett Roger | Chief Operating Officer | SELL | 6,715 | $163.18 | $1.1M |
| Mar 30, 2026 | Smith Michael Alexander | Chief Legal Officer | SELL | 19,638 | $150.98 | $3.0M |
| Mar 30, 2026 | Smith Michael Alexander | Chief Legal Officer | EXERCISE | 5,649 | $17.07 | $96.4K |
| Mar 19, 2026 | Lewis William | Chair and CEO | SELL | 1,629 | $142.17 | $231.6K |
| Mar 19, 2026 | Lewis William | Chair and CEO | EXERCISE | 6,259 | $30.46 | $190.6K |
| Mar 5, 2026 | Lewis William | Chair and CEO | EXERCISE | 6,259 | $30.46 | $190.6K |
| Mar 3, 2026 | SHAROKY MELVIN MD | Director | GIFT | 100 | — | — |
| Feb 25, 2026 | SHAROKY MELVIN MD | Director | GIFT | 1,072 | — | — |
| Feb 23, 2026 | Brennan David R | Director | GIFT | 6,000 | — | — |
| Feb 19, 2026 | Lewis William | Chair and CEO | EXERCISE | 6,259 | $30.46 | $190.6K |
| Feb 19, 2026 | Lewis William | Chair and CEO | SELL | 1,988 | $149.17 | $296.5K |
| Feb 9, 2026 | Lewis William | Chair and CEO | SELL | 4,888 | $147.17 | $719.4K |
| Feb 9, 2026 | Lewis William | Chair and CEO | EXERCISE | 4,440 | $17.16 | $76.2K |
| Feb 9, 2026 | MCGIRR DAVID W J | Director | GIFT | 53,400 | — | — |
| Feb 5, 2026 | Flammer Martina M.D. | Chief Medical Officer | SELL | 869 | $152.44 | $132.5K |
| Feb 3, 2026 | Adsett Roger | Chief Operating Officer | SELL | 791 | $156.17 | $123.5K |
| Feb 3, 2026 | Smith Michael Alexander | Chief Legal Officer | SELL | 640 | $156.27 | $100.0K |
| Feb 3, 2026 | Lewis William | Chair and CEO | SELL | 3,009 | $156.34 | $470.4K |
| Feb 3, 2026 | Bonstein Sara | Chief Financial Officer | SELL | 748 | $156.34 | $116.9K |
19 SEC filing reports analyzed. Sentiment: 5 bullish, 3 bearish, 4 mixed, 7 neutral. Avg impact: 4.9/10.
MIXED
ANALYST-UPGRADE
5/10
Jefferies initiates INSM with a Buy rating and $105 price target, below the $160.18 current price an
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
5/10
Morgan Stanley upgrades INSM to Overweight — PT $212 (+94%) as part of 7-firm cluster
May 16, 2026
MIXED
ANALYST-UPGRADE
5/10
Truist Securities initiates coverage on INSM with a Buy rating and $48 price target, below the $214.
Apr 16, 2026
MIXED
ANALYST-UPGRADE
6/10
RBC Capital initiates coverage on INSM with Outperform and a $100 price target, below the $214.79 me
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
9/10
Morgan Stanley initiated a double upgrade to Overweight from Equal-Weight with a $212 price target,
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
8/10
Barclays initiates coverage on INSM with an Overweight rating and $231 price target, implying 44% up
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
7/10
Roth Capital initiates coverage on INSM with a Buy rating and $212 price target, implying 32.3% upsi
Apr 16, 2026
MIXED
ANALYST-UPGRADE
6/10
William Blair initiates coverage on INSM with an Outperform rating, adding to recent momentum that i
Apr 16, 2026
NEUTRAL
CLUSTER
2/10
Five C-suite insiders at INSMED Inc, including the CEO and CFO, collectively sold $1.75M in open-mar
Jun 5, 2026
NEUTRAL
CLUSTER
2/10
Three top INSM insiders—CEO, CFO, and CMO—collectively sold $1.29M in open-market sales over a 7-day
Jun 5, 2026
NEUTRAL
S-3ASR
3/10
Insmed filed an automatic shelf registration (S-3ASR) covering an indeterminate amount of common sto
May 15, 2026
NEUTRAL
CLUSTER
3/10
Two C-suite insiders (CMO and CLO) sold a total of ~$981K worth of INSM shares, representing a trivi
May 15, 2026
NEUTRAL
144
2/10
Sara Bonstein, an officer of Insmed, filed a Form 144 on May 13, 2026, indicating intent to sell 8,2
May 13, 2026
NEUTRAL
CLUSTER
3/10
Insmed's CEO and CMO sold a combined $1.27M in stock within a week of a strong Q1 2026 earnings beat
May 13, 2026
BULLISH
8-K
6/10
Insmed reported Q1 2026 total revenue of $306.0M (up 230% YoY, driven by BRINSUPRI launch) and a net
May 7, 2026
BEARISH
CLUSTER
7/10
Two C-suite executives at INSMED Inc sold shares in early April, generating $4.06M in open-market pr
Apr 8, 2026
BEARISH
8-K
7/10
Insmed announced that its Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa (HS) faile
Apr 7, 2026
BEARISH
CLUSTER
5/10
Two C-suite executives at Insmed sold shares in the past week, generating $4.06 million in total pro
Apr 3, 2026
NEUTRAL
DEFA14A
3/10
Analysis based on filing metadata only — document content was unavailable
Apr 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (97% buy). Based on 29 analysts: 9 strong buy, 19 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$197.62 mean target
+102.0% upside
Strong Buy (1.23)
$140.00 Low
$243.00 High
| Metric | Value |
|---|---|
| Current Price | $97.85 |
| Target Low | $140.00 |
| Target Mean | $197.62 |
| Target Median | $202.00 |
| Target High | $243.00 |
| # Analysts | 21 |
| Recommendation | Strong Buy (1.23) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.77 | $-1.09 | $-0.58 | 54.8% | +1.2% | 4↑ 7↓ | $0.4B | 264.1% | 13 |
| Next Q 2026-09-30 |
$-0.60 | $-1.14 | $-0.35 | 65.7% | +0.6% | 3↑ 8↓ | $0.5B | 226.0% | 13 |
| Current FY 2026-12-31 |
$-2.78 | $-4.29 | $-1.84 | 56.8% | -0.0% | 4↑ 9↓ | $1.7B | 178.3% | 14 |
| Next FY 2027-12-31 |
$0.32 | $-1.91 | $1.64 | 111.7% | -2.7% | 2↑ 11↓ | $2.8B | 63.3% | 15 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.769 | |
| 7d ago | $-0.772 | +0.002 |
| 30d ago | $-0.778 | +0.009 |
| 60d ago | $-0.807 | +0.037 |
| 90d ago | $-0.868 | +0.099 |
16 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Jun 5, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 14, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| May 8, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 8, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 8, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Apr 17, 2026 | Roth Capital | REITERATE | Buy | Buy |
| Apr 14, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 1, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 30, 2026 | Morgan Stanley | UPGRADE | Equal-Weight | Overweight |
| Mar 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 24, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Mar 24, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Mar 24, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 24, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Feb 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 20, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 30, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Jan 28, 2026 | Barclays | INITIATE | — | Overweight |
| Jan 23, 2026 | Roth Capital | INITIATE | — | Buy |
| Jan 21, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 6, 2026 | UBS | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | TD Cowen | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | Guggenheim | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 19 | 1 | 0 | 0 | 97% | |
| May 1, 2026 | 9 | 18 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 9 | 16 | 1 | 0 | 0 | 96% | |
| Mar 1, 2026 | 9 | 15 | 2 | 0 | 0 | 92% | |
| Feb 1, 2026 | 9 | 16 | 2 | 0 | 0 | 93% | |
| Jan 1, 2026 | 9 | 14 | 2 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
80°
Bullish
Bearish
Neutral
Bullish
6 mentions
6 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 12, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Jun 12, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
Recent Reddit Threads
19 MAY 2026, WHAT ARE THE BIGGEST LOSERS AND WHY ?
▲ 1
💬 1
⚡ 0.5
Jun 3, 2026
short_volume
Short Volume: INSM — 66.9% short (0.5M / 0.8M)
Short: 524,135 | Exempt: 105 | TRF Vol: 783,174 | Short Ratio: 66.9% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: INSM — 67.0% short (0.8M / 1.1M)
Short: 750,047 | Exempt: 539 | TRF Vol: 1,119,034 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
May 25, 2026
dark_pool
Dark Pool: INSM — 3.4M shares, 56,515 trades
Week starting 2026-05-25. Total ATS volume: 3,413,733 shares across 56,515 trades.
May 23, 2026
Clinical Trial
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Phase Phase 3 — COMPLETED
May 23, 2026
clinical_trial_readout
Results Pending: Treprostinil Palmitil Inhalation Powder (Phase 3) — Completed 52d ago
Trial: An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-I
May 21, 2026
short_volume
Short Volume: INSM — 58.7% short (0.7M / 1.2M)
Short: 730,482 | Exempt: 25 | TRF Vol: 1,244,669 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: INSM — 5.2M shares, 76,578 trades
Week starting 2026-05-18. Total ATS volume: 5,242,343 shares across 76,578 trades.
May 14, 2026
short_volume
Short Volume: INSM — 64.2% short (0.7M / 1.1M)
Short: 709,665 | Exempt: 334 | TRF Vol: 1,105,731 | Short Ratio: 64.2% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: INSM — 57.7% short (1.6M / 2.8M)
Short: 1,603,238 | Exempt: 13 | TRF Vol: 2,780,528 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_interest
FTD: INSM — 11,691 shares ($1.4M) failed to deliver
Settlement: 20260513, Price: $116.00, FTD Value: $1,356,156, INSMED INC-NEW
May 11, 2026
dark_pool
Dark Pool: INSM — 9.9M shares, 108,672 trades
Week starting 2026-05-11. Total ATS volume: 9,920,007 shares across 108,672 trades.
May 8, 2026
short_interest
FTD: INSM — 224,501 shares ($23.6M) failed to deliver
Settlement: 20260508, Price: $105.00, FTD Value: $23,572,605, INSMED INC-NEW
May 7, 2026
earnings_calendar
INSM Q1 2026 Earnings Scheduled — 2026-05-07
May 6, 2026
short_volume
Short Volume: INSM — 62.3% short (0.5M / 0.8M)
Short: 476,618 | Exempt: 4,259 | TRF Vol: 765,237 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
May 4, 2026
dark_pool
Dark Pool: INSM — 9.8M shares, 113,766 trades
Week starting 2026-05-04. Total ATS volume: 9,814,165 shares across 113,766 trades.
May 4, 2026
short_volume
Short Volume: INSM — 62.7% short (0.5M / 0.8M)
Short: 512,502 | Exempt: 90 | TRF Vol: 817,702 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Phase Phase 2 — COMPLETED
Mar 12, 2026
Clinical Trial
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
Phase Phase 2 — COMPLETED
Feb 24, 2026
Clinical Trial
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
Phase Phase 2 — ACTIVE_NOT_RECRUITING